Skip to content

    Solara Active Pharma Sciences Q1 FY27 earnings call

    SOLARA
    Healthcare·23 Jul 2026
    Management Summary

    Solara Active Pharma Sciences Limited delivered a strong Q1 FY27, achieving its highest EBITDA and PAT in 18 quarters, driven by robust performance in its base business. The company significantly reduced its net debt and maintained focus on operational efficiency and profitable growth. However, the Ibuprofen business continues to face profitability challenges amidst volatile raw material prices and supply chain disruptions.

    Highlights

    5

    • Overall revenues stood at INR384 crores, marking a 20% year-on-year growth.

    • PAT increased by 55% year-on-year to INR16.3 crores, representing the highest PAT in the last 18 quarters.

    • Base business revenues grew 24% year-on-year to INR307 crores, demonstrating strong momentum.

    • Net debt was reduced by INR135 crores, a 22% reduction, bringing the net debt to INR479 crores as of June 30, 2026.

    • Overall EBITDA margin improved by 80 basis points quarter-on-quarter to 17%, with an absolute EBITDA of INR63.5 crores.

    Concerns

    3

    • The commodity Ibuprofen business reported a negative EBITDA margin of 12%, with an expected ongoing loss of INR10-15 crores per quarter.

    • Gross margins were marginally lower quarter-on-quarter due to raw material pricing and supply challenges, primarily triggered by geopolitical developments in West Asia.

    • Raw material availability and price volatility continue to pose risks, with instances of intermittent plant shutdowns due to shortages.

    Key financials

    Single quarter

    04 metrics
    1. 01Revenue₹384 Cr+20%YoY
    2. 02EBITDA₹63.5 Cr+10%YoY
    3. 03EBITDA Margin17%+0.8%QoQ
    4. 04PAT₹16.3 Cr+55.0%YoY

    Segment breakdown

    Base Business
    ₹307 Cr Revenue₹158 Cr Gross Margin51.5% Gross Margin %₹72 Cr EBITDA
    Ibuprofen Business
    -12% EBITDA Margin
    List

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹55 crores

    Debt

    Net ₹479 crores · 1.9x EBITDA

    Guidance & targets

    8
    CategoryTargetPriority
    Debt
    Net Debt Status
    Net debt-free
    		High
    Debt
    Net Debt-to-EBITDA Multiple
    1.7x
    		High
    Profitability
    Base Business EBITDA Margin
    25% +/- 1%
    		Medium
    Profitability
    Ibuprofen EBITDA Loss
    INR10-15 crores negative
    		High
    Profitability
    Base Business Gross Margin
    52-55%
    		High
    Revenue
    Base Business Revenue Growth
    10% YoY
    		High
    Capex
    FY27 Capex
    INR55-60 crores
    		High
    Capex
    Average Annual Capex
    INR40-50 crores
    		High

    What to watch in Q2 FY27

    5

    Ibuprofen Strategic Review Outcome

    September (Q2 FY27)
    CurrentOngoing, decision expected H1 FY27
    TargetSpecific solution/decision announced

    Why it matters

    The resolution of the loss-making Ibuprofen business is crucial for overall profitability and capital allocation.

    I think you should be expecting something coming your way in H1. All we can say today is we are working towards what we think is a optimum solution to the issue. We feel fairly confident💬 that the solution will come out of it. And I would like to address this question in the September time.

    Risks & concerns

    4
    RiskSeverity

    Geopolitical developments and West Asia crisis

    Triggered higher raw material prices and supply chain challenges, impacting gross margins and raw material availability. — Management acknowledged

    high

    Raw material availability and price volatility

    Petroleum-dependent APIs and solvent shortages lead to intermittent plant shutdowns and increased costs, which are not always fully passable to customers. — Management acknowledged

    high

    Ibuprofen business continued losses

    The Ibuprofen business continues to face profitability challenges, reporting a negative 12% EBITDA margin and expected INR10-15 crores negative EBITDA loss per quarter. — Management acknowledged

    medium

    New US tariff schemes

    Announcement of new US tariffs, but no formal policy or legal framework yet, awaiting clarification on product scope (APIs vs. formulations). — Management not addressed

    low

    Q&A highlights

    8

    “I think you should be expecting something coming your way in H1. All we can say today is we are working towards what we think is a optimum solution to the issue. We feel fairly confident that the solution will come out of it. And I would like to address this question in the September time.”

    Confirms the timeline for a critical strategic decision regarding the loss-making Ibuprofen business.

    asked by Sajal Kapoor

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Q1 FY27 Performance Driven by Base Business

    Solara Active Pharma Sciences Limited reported a stellar Q1 FY27, achieving its highest EBITDA and PAT in the last 18 quarters. Overall revenues grew 20% year-on-year to INR384 crores, while PAT surged 55% year-on-year to INR16.3 crores. The base business was a key driver, with revenues increasing 24% year-on-year to INR307 crores and EBITDA growing 8% year-on-year to INR72 crores, demonstrating strong operational execution and focus on profitable growth.

    02

    Ibuprofen Business Continues to Face Profitability Headwinds

    In contrast to the base business, the commodity Ibuprofen segment continues to struggle with profitability, reporting a negative EBITDA margin of 12%. While there was a marginal sequential improvement, management expects an ongoing EBITDA loss of INR10-15 crores per quarter. The business faces challenges from raw material price volatility and supply shortages, though a strategic review for this segment is underway, with an update expected in September.

    03

    Significant Debt Reduction and Balance Sheet Strengthening

    The company made substantial progress in strengthening its balance sheet, reducing net debt by INR135 crores (a 22% reduction) during the quarter. This reduction was primarily funded by INR100 crores from the rights issue in May 2026 and INR35 crores from operational cash flows. As of June 30, 2026, net debt stood at INR479 crores, resulting in a net debt-to-EBITDA multiple of 1.9x, with a target to further reduce this to 1.7x by March 2027.

    04

    Strategic Capital Allocation Focused on Debottlenecking

    Solara's capital allocation strategy for FY27 involves a committed capex of INR55-60 crores, with an average of INR40-50 crores planned for FY28 and FY29. The majority of this capex, approximately INR40 crores, is earmarked for incremental debottlenecking of existing capacities to support high-margin products, aiming for a 20-30% capacity expansion with a quick payback period of 2-3 quarters. Greenfield expansion is not a current priority, with focus remaining on optimizing existing assets.

    05

    External Headwinds and Raw Material Challenges

    The company continues to navigate significant external headwinds🌐, particularly the West Asia crisis, which has led to higher raw material prices and supply chain disruption🌐s. These factors contributed to marginally lower gross margins quarter-on-quarter. While Solara has been transparent with customers, enabling the pass-through of some cost increases, raw material availability remains a challenge, occasionally leading to intermittent plant shutdowns.

    06

    Operational Priorities and Sustainable Growth Outlook

    Management outlined three key operational priorities: expanding existing and seeding new businesses, driving operational efficiency through debottlenecking, and optimizing working capital to generate free cash. The base business is expected to sustain a 10% year-on-year revenue growth, with a target EBITDA margin of 25% +/- 1% and a gross margin range of 52-55%, reinforcing confidence in its long-term growth potential.

    This is an AI-generated summary of a publicly available earnings call transcript.